title: A randomised controlled trial comparing a dietary antiplatelet, the water-soluble tomato extract Fruitflow, with 75 mg aspirin in healthy subjects.
abstract: Increasing numbers of food ingredients are gaining acknowledgement, via regulated health claims, of benefits to human health. One such is a water-soluble tomato extract, Fruitflow (FF), a dietary antiplatelet. We examined relative platelet responses to FF and to 75 mg aspirin (ASA) in healthy subjects.
  
  
  
  A total of 47 healthy subjects completed a double-blinded randomised controlled trial following a crossover design. Acute and 7-day treatments with 75 mg ASA were compared with control with and without concomitant FF, over a 5-h timecourse. Platelet aggregation response agonist, platelet thromboxane A2 release, plasma clotting times and time to form a primary haemostatic clot (PFA-100 closure time, TTC) were measured.
  
  
  
  Administration of all treatments lowered platelet function and thromboxane A2 generation, and extended the TTC, relative to baseline (P<0.001) and to control (P<0.001). Plasma clotting times were not affected. A single 75 mg dose of ASA showed approximately equal efficacy to a dose of FF, whereas daily 75 mg ASA was approximately three times as effective after 7 days (P=0.002). Platelet responses were heterogenous with distinct weak and strong responder groups. Weak ASA responders retained a functional platelet response to collagen agonist and were responsive to FF. Concomitant FF and ASA did not lead to significant additive effects.
  
  
  
  The suppression of platelet function observed after consuming FF is approximately one-third that of daily 75 mg ASA. The reversible action of FF renders it less likely to overextend the time to form a primary haemostatic clot than ASA, an important safety consideration for primary prevention.
authors.affiliation: Provexis Plc, London, UK.
authors.forename: N
authors.initials: N
authors.lastname: O'Kennedy
authors.affiliation: Provexis Plc, London, UK.
authors.forename: L
authors.initials: L
authors.lastname: Crosbie
authors.affiliation: Provexis Plc, London, UK.
authors.forename: H-J
authors.initials: HJ
authors.lastname: Song
authors.affiliation: Provexis Plc, London, UK.
authors.forename: X
authors.initials: X
authors.lastname: Zhang
authors.affiliation: Bioinformatics and Statistics Scotland (BioSS), Dundee, UK.
authors.forename: G
authors.initials: G
authors.lastname: Horgan
authors.affiliation: Department of Nutrition, Institute for Basic Medical Sciences, Faculty of Medicine, University of Oslo, Blindern, Oslo, Norway.
authors.forename: A K
authors.initials: AK
authors.lastname: Duttaroy
mesh_terms: D000368:Aged; D016718:Arachidonic Acid / Q000097:blood; D001241:Aspirin / Q000494:pharmacology*; D001792:Blood Platelets / Q000187:drug effects / Q000378:metabolism; D018592:Cross-Over Studies; D004032:Diet; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D018551:Solanum lycopersicum / Q000737:chemistry*; D008297:Male; D008875:Middle Aged; D010936:Plant Extracts / Q000494:pharmacology*; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D010979:Platelet Function Tests; D013929:Thromboxane B2 / Q000378:metabolism
chemical_list: D010936:Plant Extracts; D010975:Platelet Aggregation Inhibitors; D016718:Arachidonic Acid; D013929:Thromboxane B2; D001241:Aspirin